215 related articles for article (PubMed ID: 18083041)
21. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
22. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
23. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
24. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Chou LS; Garey J; Oishi K; Kim E
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
[TBL] [Abstract][Full Text] [Related]
25. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
26. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886
[TBL] [Abstract][Full Text] [Related]
27. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Lacouture ME; Hwang C; Marymont MH; Patel J
J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
[No Abstract] [Full Text] [Related]
28. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
30. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
[TBL] [Abstract][Full Text] [Related]
31. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
[TBL] [Abstract][Full Text] [Related]
32. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike A; Yamamoto N; Tanaka H; Yanagitani N; Kudo K; Ohyanagi F; Ono A; Naito T; Murakami H; Horai T; Nishio M
Anticancer Res; 2014 Apr; 34(4):1975-81. PubMed ID: 24692734
[TBL] [Abstract][Full Text] [Related]
34. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Wheatley-Price P; Ding K; Seymour L; Clark GM; Shepherd FA
J Clin Oncol; 2008 May; 26(14):2350-7. PubMed ID: 18467727
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
36. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Burotto M; Manasanch EE; Wilkerson J; Fojo T
Oncologist; 2015 Apr; 20(4):400-10. PubMed ID: 25795635
[TBL] [Abstract][Full Text] [Related]
39. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
40. Newly recognized ocular side effects of erlotinib.
Methvin AB; Gausas RE
Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]